KROS Tiesioginiai signalai | Didinkite pelną su Getagraph.com

PARDAVIMAS 93564 min ago

@ $58.15

Išleistas: 14 vas. 2024 @ 22:11

Grąža: -1.39%

Ankstesnis signalas: vas. 13 - 16:30

Ankstesnis signalas: Pirkimas

Grąža: 4.68 %

Live Chart Being Loaded With Signals

Commentary (19 bal. 2024 @ 22:34):

Stats
Šios dienos apimtis	205 392
Vidutinė apimtis	378 072
Rinkos kapitalizacija	2.06B
EPS	$-1.340 ( 2024-03-01 )
Kita pelno data	( $-1.310 ) 2024-05-02
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-11.03
ATR14	$0.114 (0.20%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-23	Seehra Jasbir	Buy	125 000	Employee Stock Option (right to buy)
2024-02-13	Seehra Jasbir	Buy	125 000	Employee Stock Option (right to buy)
2024-02-13	Regnante Keith	Buy	40 000	Employee Stock Option (right to buy)
2024-02-13	Rovaldi Christopher	Buy	150 000	Employee Stock Option (right to buy)
2024-02-13	Cooper Simon Peter	Buy	40 000	Employee Stock Option (right to buy)

INSIDER POWER
67.40
Last 96 transactions
Buy: 1 546 013 \| Sell: 365 314

Tūris Koreliacija

Ilgas: -0.08 (neutral)

Trumpas: -0.28 (neutral)

Signal:(53.529) Neutral

Keros Therapeutics Inc Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
PRAX	0.919
CDNA	0.904
HNNA	0.894
RPAY	0.889
TTEC	0.888
EWTX	0.883
SMSI	0.882
SRAX	0.879
ANNX	0.876
LPCN	0.874

10 Labiausiai neigiamai susiję koreliacijos
CNST	-0.811
UNCY	-0.801

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Keros Therapeutics Inc Koreliacija - Valiuta/Žaliavos

0.13
( neutral )

0.06
( neutral )

0.00
( neutral )

0.09
( neutral )

-0.01
( neutral )

-0.27
( neutral )

Keros Therapeutics Inc Finansinės ataskaitos

Annual	2023
Pajamos:	$151 000
Bruto pelnas:	$-664 000 (-439.74 %)
EPS:	$-5.20

Q4	2023
Pajamos:	$143 000
Bruto pelnas:	$-104 000 (-72.73 %)
EPS:	$-1.340

Q3	2023
Pajamos:	$8 000.00
Bruto pelnas:	$-543 000 (-6 787.50 %)
EPS:	$-1.330

Q2	2023
Pajamos:	$0
Bruto pelnas:	$-545 000 (0.00 %)
EPS:	$-1.270

Financial Reports:

No articles found.

Keros Therapeutics Inc

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, and is currently in Phase 1 clinical trial; and KER-012, which is in Phase 1 clinical trial to treat disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension. The company was incorporated in 2015 and is headquartered in Lexington, Massachusetts.